CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Surgical site infections and antimicrobial resistance remain major challenges globally
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Jaypirca is making waves in the fight against B-cell malignancies
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
Subscribe To Our Newsletter & Stay Updated